Igenomix Information

The Vitrolife Group is a world-leading global provider of medical devices and genetic testing testing solutions. Dedicated to the reproductive-health market since 1994, we have grown by focusing on product development, groundbreaking research, consistent quality control and acquisitions of innovative companies in the industry. In 2021, Vitrolife acquired Igenomix, a leader in reproductive genetic testing services primarily for IVF clinics. Together we are now the Vitrolife Group, a global leader in reproductive health focused on supporting our customers and patients worldwide to improve treatment outcomes – always with sustainability in mind. Based on science and advanced research capabilities, our aim is to deliver products and services for the entire reproductive-health journey, providing consistent performance and guaranteed quality. Currently, we are approximately 1,100 people worldwide headquartered in Gothenburg, Sweden. Our products and services are available in more than 125 countries, through our own presence in more than 25 countries and a vast network of distributors for the rest of the world. We are on a mission to be the leading valued solution provider in reproductive health and to support customers with successful treatment outcomes.